Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps.

Publication date: Jan 31, 2024

Increased dupilumab utilization coincided with decreased ESS in patients with CRSwNP between 2019 and 2021. One potential confounder was the concurrent COVID-19 pandemic, which may have negatively impacted surgery utilization rates.

Concepts Keywords
Allergy chronic rhinosinusitis
Covid endoscopic sinus surgery
Decreased FESS
Rhinosinusitis therapeutics


Type Source Name
drug DRUGBANK Dupilumab
disease MESH nasal polyps
disease MESH COVID-19 pandemic
disease MESH rhinitis

Original Article

(Visited 1 times, 1 visits today)